Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Samolet will build a residential complex of more than 500 thousand square meters in Marushkinskoe

3/31/23 SMLT

Lenta opens its own points of sale of tobacco products Tobacco Point

3/31/23 LENT

RuStore's share of app stores in Russia rose to 2%

3/31/23 VKCO

Segezha sold assets in Europe

3/31/23 SGZH

Sakhalinenergo reported for 2022 according to RAS

3/31/23 SLEN

Segezha reported for 2022 according to IFRS

3/31/23 SGZH

Stavropolenergosbyt's RAS profit doubled in 2022

3/30/23 STSB

VK consolidates 100% of the Sphereum educational service for schoolchildren

3/30/23 VKCO

Russia asked South Africa to help Yandex find partners to launch cab and delivery services

3/30/23 YNDX

MKB reported for 2022 according to RAS

3/30/23 CBOM